Best Hospitals, U.S. News and World Report, National Ranked in 13 specialties - 2014-15

Duke University Hospital: consistently ranked among the nation's best.


Continuing Medical Education (CME)

HCV Treatment: Incorporating Glecaprevir/Pibrentasvir and Sofosbuvir/Velpatasvir/Voxilaprevir Into Clinical Practice


Online Publication
Cost: Complimentary
Credit: .25 AMA PRA Category 1 Credit

Andrew Muir, MD

This 15-minute activity features a brief video introduction by faculty expert Dr. Muir in which he discusses how the new combination therapies glecaprevir/pibrentasvir and sofosbuvir/velpatasvir/voxilaprevir have changed the treatment landscape. The activity then continues with a text-based review of the recent advances in direct-acting antiviral (DAA) treatment for hepatitis C virus (HCV) and the clinical trials that led to the approval of these new agents.

In collaboration with

We hope you have been enjoying your complimentary subscription to Clinical Practice Today from Duke Health. Do you have comments, suggestions, or ideas? If so, we'd love to hear from you!
Entry deadline: February 28, 2018.